(By Balaseshan) Apricus Biosciences Inc. (NASDAQ:APRI : 3, 0.18) said its subsidiary has entered into an exclusive license agreement with Takeda Pharmaceuticals International GmbH to market Vitaros, a treatment for erectile dysfunction, in the United Kingdom.
Apricus Biosciences Inc. is a drug delivery system & technologies.
Under the terms of the agreement, Takeda will pay NexMed U.S.A., a subsidiary of Apricus Biosciences, an undisclosed upfront payment, and milestone payments of up to 35 million euros.
According to market researcher IMS Health, the erectile dysfunction market (ED) in the U.K. was valued at 202 million euros in 2011, or US$260 million.
Vitaros is a topically delivered formulation (cream) of alprostadil (a vasodilator) supplied in a single dose dispenser (AccuDose), for the treatment of erectile dysfunction (ED). It is delivered with Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus' proprietary NexACT delivery technology.
 |
| Apricus Biosciences |
Under the terms of the agreement, Takeda will pay NexMed U.S.A., a subsidiary of Apricus Biosciences, an undisclosed upfront payment, and milestone payments of up to 35 million euros.
According to market researcher IMS Health, the erectile dysfunction market (ED) in the U.K. was valued at 202 million euros in 2011, or US$260 million.
Vitaros is a topically delivered formulation (cream) of alprostadil (a vasodilator) supplied in a single dose dispenser (AccuDose), for the treatment of erectile dysfunction (ED). It is delivered with Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus' proprietary NexACT delivery technology.
0 comments:
Post a Comment